Lipocine Inc. (LPCN)
NASDAQ: LPCN · Real-Time Price · USD
8.13
-0.06 (-0.73%)
At close: Mar 6, 2026, 4:00 PM EST
8.10
-0.03 (-0.37%)
After-hours: Mar 6, 2026, 5:48 PM EST
Lipocine Employees
Lipocine had 16 employees as of December 31, 2024. The number of employees decreased by 1 or -5.88% compared to the previous year.
Employees
16
Change (1Y)
-1
Growth (1Y)
-5.88%
Revenue / Employee
$270,168
Profits / Employee
-$342,202
Market Cap
45.14M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Acrivon Therapeutics | 78 |
| Aligos Therapeutics | 70 |
| NextCure | 43 |
| LeonaBio | 26 |
| MiNK Therapeutics | 23 |
| Apollomics | 13 |
| Telomir Pharmaceuticals | 9 |
| Lite Strategy | 4 |
LPCN News
- 17 days ago - Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD) - PRNewsWire
- 6 weeks ago - Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) - PRNewsWire
- 7 weeks ago - Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) - PRNewsWire
- 2 months ago - Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone - PRNewsWire
- 3 months ago - Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) - PRNewsWire
- 4 months ago - Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025 - PRNewsWire
- 4 months ago - Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek® - PRNewsWire
- 5 months ago - Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD) - PRNewsWire